Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Novo Nordisk
Insulin detemir lessens blood glucose variability in study
June 26th, 2004
Insulin detemir, a long-acting basal insulin analog in late-stage development, was found to vary less in absorption and effect on blood glucose compared to neutral protamine Hagedorn (NPH) insulin or insulin glargine in people with type 1 diabetes, according to a study published in Diabetes. In this first study (clamp) to systematically compare these three basal insulins, the results showed insulin detemir had less intrapatient variability of blood glucose than both NPH insulin and insulin glargine. "Absorption, intrapatient variability and the metabolic action of insulin therapy are issues many clinicians and diabetes patients struggle with...
Source: Law & Health Weekly (2004-06-26)
|
